Cambridge, United States
Parabilis Medicines™ is a clinical-stage biopharmaceutical startup founded in 2016 with the mission to develop transformative medicines for severe diseases. The company operates in the Biotechnology and Pharmaceutical industries, targeting historically undruggable protein targets using its proprietary Helicon platform. Helicons are helical peptides designed to modulate protein interactions, offering breakthroughs where conventional therapies fall short.
Recently, Parabilis Medicines secured a significant $305.00M Series F investment as of 01 January 2026. The investment round saw participation from prominent investors like Arch Venture Partners, GV, HBM Healthcare Investments, and RA Capital Management, among others. Such robust backing indicates strong confidence in the company's innovative approach and potential for groundbreaking impact on human health.
Overall, Parabilis Medicines appears well-positioned to advance its pipeline and extend the frontiers of drug discovery.
